Will MindMed Partner With Johnson & Johnson for 18MC? ( MNMD & J&J In the Speculation Zone)

There were A LOT OF DEVELOPMENTS THIS WEEK, so strap on your seat belts and let’s dive into what happened this week with: MindMed ( MMED / MNMD / MMQ ), Compass Pathways (CMPS), NUMINUS (NUMI), Fieldtrip Health (FTRP / FTRPF), Mydecine ( MYCO / MYCOF), HAVN Labs
( HAVN / HAVLF), Novamind ( NM / NVMDF), Champignon Brands aka Braxia Scientific
(old ticker :SHRM / new ticker: BRAX / BRAXF), Nova Mentis (NOVA / NMLSF) and Small Pharma (DMT).

Timestamps:
0:00 – Intro
0:54 – MindMed’s (MMED / MNMD) Project Angie Announcement
1:47 – Compass Pathways (CMPS) Q1 Financial Results Date & Business Updates
3:16 – Analyst Coverage and Buy Ratings for CMPS
4:35 – Mydecine ( MYCO / MYCOF) 2020 Financial Results & Business Highlights
9:17 – Numinus Wellness (NUMI) Q2 Financial Results
11:25 – Field Trip Health (FTRP/ FTRPF) Opens more clinics
12:19 – Novamind ( NM / NVMDF) doubling its clinics
14:25 – Champignon Brands (SHRM /SHRMF) changing its named to Braxia Scientific (BRAX / BRAXF)
15:31 – NEW DMT company that began trading on may 6th under the name SMALL PHARMA ( DMT)
17:19 – HAVN Labs (HAVN) opens a new lab in Jamaica
17:50 – Nova Mentis launches a new clinical study using psilocybin to treat autism

Link to MindMed’s Project Angie Press release:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

Link to Compass Pathways Q1 financial Results date:
https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announce-first-quarter-2021-financial

Link to Compass Pathways (CMPS) analyst ratings: https://www.marketbeat.com/stocks/NASDAQ/CMPS/price-target/

Link to Mydecine ( MYCO/ MYCOF) Full Year 2020 Financial results Plus business updates
https://www.globenewswire.com/news-release/2021/05/03/2221266/0/en/Mydecine-Reports-Full-Year-2020-Financial-Results-and-Provides-Business-Update.html

Link to Numinus (NUMI) Q2 2021 Financial Results:
https://www.newswire.ca/news-releases/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing-mindspace-wellbeing-acquisition-and-clinical-trial-collaboration-with-maps-pbc-846735411.html

Link to Field Trip’s (FTPR / FTPRF) 7th Psychedelic-assisted therapy Clinic:
https://psilocybinalpha.com/news/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston-locations-of-next-5-field-trip-health-centers

Link to Novamind’s (NM / NVMDF) Ketamine Clinic article:
https://novamind.ca/2021-05-04-novamind-doubles-in-size-adds-four-new-psychedelic-mental-health-clinics/

Link to Champignon Brands ( SHRM/ SHRMF) announcing their name change to Braxia Scientific (BRAX / BRAXF):
https://thedeepdive.ca/champignon-brands-to-change-name-to-braxia-scientific/

Link to Small Pharma ( DMT):
https://psilocybinalpha.com/news/small-pharma-completes-reverse-take-over-transaction

Link to Havn’s (HAVN / HAVLF) Jamaica lab:
https://www.psychedelicfinance.com/articles/havn-labs-jamaica-facility-now-fully-operational

Link to Nova Mentis launching a clinical study to learn more about Autism:
https://psilocybinalpha.com/news/nova-mentis-launches-autism-clinical-study

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Numi #CMPS

The psychedelic medicines industry had a revolutionary year in 2021. At the start of the year, there were only a couple of publicly traded companies, but by the end of it, there were dozens. These companies are racing to answer questions such as: Can psychedelics cure depression? Can psychedelic treat anxiety? And, can psychedelics help with mental health?

Though the answers to these questions have not been proven 100%, after 2021, it does appear more likely than not that the answer to some of these at least, is yes. In this video, we will recap some of the most significant milestones of the psychedelics industry in 2021, and end it with what I am looking forward to in the new year.

The first big story of 2021 was the IPOs. Though MindMed (MNMD/MMED) and Compass Pathways (CMPS) went public in 2020, companies such as Field Trip Health (FTRP), Numinus Wellness (NUMI), atai Life Sciences (atai), Cybin Corp (CYBN), and dozens of others joined them in 2021. Add to this the launch of ETFs such as the Horizons Psychedelics ETF (PSYK) and the Advisor Shares Psychedelics ETF (PSIL), and 2021 was a huge year for the advent of public companies in the psychedelic medicines space.

The next big story was uplistings. Not all stock markets are created equal. In order to have the prestigious needed to attract serious money, companies need to be on exchanges such as the Nasdaq, NYSE, and the TSX. In 2021 we saw MindMed, Numinus, Field Trip, Cybin, and more join the big boys league.

Third, was funding. Psychedelic companies are for the most part biotech companies. In order to get a new drug through the clinical trial process, it takes hundreds of millions of dollars. This year we saw atai, Compass, MindMed, Cybin, and Field Trip, among others, raise over a billion dollars for the industry. This will sustain them for years to come.

And finally, 2021 saw a few high-profile clinical trials. The most significant was the MAPS Phase 3 clinical trial, which treated PTSD with MDMA-assisted therapy. The results of this trial were earth-shattering. Equally important was the Compass phase 2b trial, treating treatment-resistant depression with Psilocybin.

Moving into the new year, I am excited to see more clinical trials, and I expect to see mergers in the field.

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy
@Psychedelic Spotlight

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Psychedelics #MindMed #Psylocybin

In today’s episode, we discuss :MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF).

2020 was a wild year for MindMed, with the company IPOing in March, at just over 20c/ share, all prices in American currency. Then, the MindMed stock price shot up to a high of $4.37 in December, only to fall about 30% and consolidate around $3 a share in the new year.

But what will be the main catalysts for MindMed and its stock going forward in 2021? Put another way, what are the events and dates that shareholders and potential investors should circle on their calendars?

In this episode, we are going to talk about several catalysts to look out for
1. MindMed’s Nasdaq uplisting
– When to expect MindMed to join the Nasdaq?
– Is MindMed’s uplisting a sure thing?
-What will happen to MindMed stock if/when the company gets uplisted?

2. Clinical trials wrapping up, and data being released by MindMed
– Important dates MindMed investors should circle in their calendars
3. MindMed’s quarter end financial reporting
4. MindMed conference calls

Unknown Catalysts for Mindmed:
1. Clinical trials expansions
2. Financial agreements

** Also, on the 20th of January, Kevin O’Leary and Jr Rahn went live discussing MindMed. For those who haven’t seen it, Jr mentioned a few extra catalysts we should be looking forward to which we will discuss in our next episode.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://www.prnewswire.com/news-releases/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round-301178915.html

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF